Exit markets are felt the pinch, but corporate acquisitions have continued to display remarkable strength.
Aberdeen’s Peter Denious chats about the unicorn fallout and managing venture portfolios
IPOs come back from the dead, thanks to four VC-backed biotech companies debuting
Funds from Column Group and OrbiMed are off to good starts, while those from Khosla and Cannann aren’t distinguishing themselves from the pack
Vanedge Capital has held an initial close of its second information technology fund on the strength of several big portfolio wins, including last year’s sales of MediaCore, Metafor and Recon. Vanedge II raised $104 million in committed capital in January, Vanedge Managing Partner Moe Kermani told PE Hub Canada. That puts the fund over half way to meeting its $200 million target.
Vancouver-based investor, which backs North American tech companies, expects a final close within the next 12 months
Quarter-to-date fundraising shows U.S.-based firms have raised more than $6.3 billion in the start of the new year, although there appears to be a slowdown in the closings in smaller funds
Venture funds from DCM, Darwin Ventures and the Column Group showed handsome gains through early last year in the University of California portfolio.
Hearing-focused startups are bridging the gap of consumer electronics and healthcare, as hearing ailments become increasingly prevalent among younger people
Toronto-based investment firm Kensington Capital Partners has exceeded the target it set for Kensington Venture Fund (KVF) in the fund of funds’ final close. KVF, the second fund closed in partnership with Ottawa’s Venture Capital Action Plan, raised $306 million, with most recent commitments coming from a mix of family offices, individual investors, private foundations and wealth managers.